- Open $2.3000
- Day Range 2.2100 - 2.3899
- 52 Week Range 2.1500 - 41.2500
- Market Cap $26.5M
- Shares Outstanding 12.21M
- Public Float 11.27M
- Beta 0.62
- Rev. per Employee $103.29K
- P/E Ratio N/A
- EPS -$8.6075
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 496.04K 08/15/22
- % of Float Shorted 4.40%
- Average Volume 566.36K
Shares of Athersys Inc. shot up 26.5% in premarket trading Monday, after the company said it has received Food and Drug Administration authorization to start a phase 2/3 trial to assess safety and efficacy of its MultiSte...
Athersys gets FDA OK for phase 2/3 to study MultiStem in patients with COVID-19-induced ARDS
Athersys stock price target raised to $8 from $6 at Maxim Group
Barron's Four Biotech Picks for Cures Law
Athersys stock price target raised to $10 from $5 at Maxim Group
After 13 years, the Food and Drug Administration has opened the door to fat profits for astute investors from fat pills.
BOSTON (江湖电竞最新版比赛(江湖电竞投注app网站)) -- A federal judge on Wednesday upheld the Obama Administration's decision to restore federal funding for certain types of embryonic stem-cell research, according to reports. A U.S. District Court in ...
Shares of several stem-cell companies jumped Friday on reports that stem-cells were used to grow an artificial trachea to treat a patient stricken with advanced cancer.
SIGA shares are falling on news that the company may lose a government contract because the Small Business Administration does not consider it a small business.
Early sector gainers include a pair of smaller companies, Chelsea Therapeutics and Athersys.
BOSTON (江湖电竞最新版比赛(江湖电竞投注app网站)) -- A federal appeals court on Thursday ruled that federal funding of embryonic stem-cell research projects will continue while a recent judge's ruling against such funding is under appeal, according to...
Shares of stem-cell researchers regain ground, after being pushed down earlier in the week on investor concerns that a court ruling against the federal funding of embryonic stem-cell research would negatively impact the fl...
BOSTON (江湖电竞最新版比赛(江湖电竞投注app网站))-- Shares of many of the publicly-traded stem cell researchers lost ground Tuesday, the day after a federal judge blocked a recent government decision to expand federal funding for certain types of embr...
BOSTON (江湖电竞最新版比赛(江湖电竞投注app网站)) -- Biodel Inc. led drug stocks south early Tuesday as shares of the biotech company fell on news that the U.S. Food and Drug Administration has issued a warning letter to one of its contract product ma...
AMAG Pharmaceuticals Inc. shares fell in afternoon trading Thursday, the day after the company issued an earnings report that fell shy of Wall Street expectations.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.